Favorable Short-Term and Long-Term Outcomes among Patients with Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation

Anat Berkovitch, Victor Guetta, Israel M. Barbash, Noam Fink, Ehud Regev, Elad Maor, Yotam Vered, Yoni Grossman, Arwa Younis, Rafael Kuperstein, Micha Feinberg, Elad Asher, Amit Segev, Paul Fefer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Transcatheter aortic valve replacement (TAVR) is now the treatment of choice for high-surgical risk patients with symptomatic aortic stenosis. Little is known regarding the outcome of TAVR in patients with previous malignancy. METHODS: We investigated 477 patients who underwent TAVR in a tertiary medical center. Subjects were divided into two groups according to malignancy status: no history of malignancy (n ≤ 386) and positive history of malignancy (n ≤ 91). RESULTS: Mean age of the study population was 81 ± 7 years, and 52% were men. No major differences in baseline characteristics were found between groups. All-cause mortality was 24% for both malignancy and non-malignancy groups at a mean follow-up of 851 ± 629 days. Kaplan-Meier survival analysis demonstrated no difference in all-cause mortality between groups. Multivariate Cox regression analysis showed that malignancy status did not affect prognosis regarding overall mortality (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.5-1.4; P≤.46). However, cancer therapy administered within 12-months of TAVR was significantly associated with increased total mortality among patients undergoing TAVR (HR, 4.38; 95% CI, 1.14-16.77; P≤.03). CONCLUSIONS: Malignancy is a common comorbidity among TAVR candidates. Mere history of malignancy among elderly patients does not adversely affect short-term or long-term outcomes after TAVR; however, history of recent (<1 year) cancer-related treatment increases the risk for long-term mortality after TAVR. Decisions regarding TAVR among oncological patients should be individualized according to their malignancy status and anticipated life expectancy.

Original languageEnglish
Pages (from-to)105-109
Number of pages5
JournalJournal of Invasive Cardiology
Issue number3
StatePublished - Mar 2018


  • aortic stenosis
  • aortic valve disease
  • transcatheter aortic valve replacement


Dive into the research topics of 'Favorable Short-Term and Long-Term Outcomes among Patients with Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation'. Together they form a unique fingerprint.

Cite this